Bibliografía
 

2. Pool-Wilson PA. Hearth failure. Medicine International, 1986: 2: 866-871.

3. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive hearth failure. The Framinghan Study. N. Engl. Med. 1971; 285: 1441

4. Ferreira Montero I. Insuficiencia cardiaca. Visión actual. pp 18-21.

5. Braunwald E. Pathogenesis of hearth failure: Then and now. Medicine 70: 68. 1991.

6. Soufer R. Intact systolic left ventricular function in clinical congestive hearth failure. Am. J. Cardiol. 1984: 55: 1031-1036.

7. Schlant RC. Normal physiology of the cardiovascular system. The Hearth. New York. McGraw-Hill 1994: 113-152.

8. Ganav et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. JACC 1992; 19: 1550-1558.

9. Meerson FZ. The myocardium in hiperfunction, hypertrophy and hearth failure. Circ. Res. 25 (Suppl 2): 1, 1969.

10. Cruickshank JM. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J. Hum. Hypertens 1992; 6: 85-90.

11. Harris P. Congestive cardiac failure: central role of arterial pressure. Br. Hearth J. 1987; 58: 190-203.

12. Mann DL et al. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circ. 1992: 85: 790-804.

13. Tan LB. Cardiac Myocyte necrosis induced by angiotensin II. Circulation Res. 1991: 69:1185-1195.

14. Francis GS et al. The neurohumoral axis in congestive hearth failure. Ann. Inter. Med. 101: 370: 1984.

15. Ferreira IJ. Aspectos actuales de los sistemas renina-angiotensina hísticos, péptido atrial natriurético y prostaglandinas en la hipertensión arterial. Rev Esp Card. 1990: 43 (suplemento 1) 24-33.

16. Poole-Wilson PA. Chronic heart failure: cause, pathophysiology, prognosis, clinical manifestations, investigations. En: Julian DG, Camm AJ, Fox KF, Hall RJC, Poole-Wilson PA, eds. Diseases of the Heart. London: Balliere-Tindall, 1989: 24-36.

17. Guyton AC, Jones CE, Coleman TG: Circulatory physiology: cardiac output and its regulation. En: Guyton AC, ed. Philadelphia:WB Saunders, 1973.

18. Starling EH. On the absorption of fluids from the connective tissue spaces. J Physiol 1896; 19: 312-326.

19. Crapo JD. New concepts in the formation of pulmonary edema. Am Rev Respir Dis 1993, 147: 790-792.

20. West JB, Tsukimoto K, Mathieu-Costello O, Prediletto R. Stress failure in pulmonary capillaries. J Appl Physiol 1991, 70: 1731-1742.

21. Kurz RW, Stockenhuber F, Gremmel F, Graninger W. Serum concentrations of inmune parameters during acute cardiogenic pulmonary edema. Crit Care Med 1992, 20: 1235-1242.

22. Doyle IR, Nicholas TE, Bersten AD. Serum sufactant protein-A levels in patients with acute cardiac pulmonary edema and adult respiratory distress syndrome. Am J Respir Crit care med 1995, 152: 307-317.

23. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989, 261: 884.

24. West JB. Ventilation/Blood flow and Gas Exchange, 3th ed.. Oxford, England, Blackwell, 1977, p 22.

25. Beyers JA. Radiologic features of pulmonary edema. S Afr Med J 1979, 55: 792.

26. Heikkila J, Hugenholtz PG, Tobakin BS. Prediction of left heart filling pressure and its sequential change in acute myocardial infarction from the terminal force of the P wave. Br Heart J 1973, 35:142.

27. Criteria Committee, New York Heart Association. En: Diseases of the heart and Blood Vessels. Nomenclature and Criteria for Diagnosis, 6th ed. Boston, Little, Brown and Co., 1964, p. 114.

28. Lorell BH. Significance of diastolic dysfunction of the heart. Annu Rev Med 1991, 42: 411-436.

29. Braunwald E, Sonnenblick EH, Ross J. Mecanismos de contracción y relajación cardíacas. En: Braunwald E ed., Tratado de cardiología, Interamericana-McGraw Hill, 1993, p. 391-438.

30. Stauffer JC, Gaasch WH. Recognition and treatment of left ventricular diastolic dysfunction. Prog Cardiovasc Dis 1990; 32: 319-332.

31. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA, Management of heart failure III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994; 272: 1528-1534.

32. Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging: report of the American College of Cardiology/American Heart Association Task Force on Assesment of Diagnostic and Therapeutic Cardiovascular Procedures (Commitee on Radionuclide imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995; 25: 521-547.

33. Dagianti A, Penco M, Agati L, et al. Stress echocardiography: comparison of exercise, dipyridamole and dobutamine in detecting and prediciting the extent of coronary artery disease. J Am Coll Cardiol 1995; 26: 18-25.

34. Perrone-Filardi P, Pace L, Prastaro M, et al. Dobutamine echocardiography predicts improvement of hypoperfused dysfunctional myocardium after revascularization in patients with coronary artery disease. Circulation 1995; 91: 2556-2565.

35. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331: 1564-1575.

36. Williams JF, Bristow MR, Fowler MB, et al. Guidelines for the Evaluation and Management of Heart Failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995; 92:2764-2784.

37. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. Circulation 1996, 94; 2285-2296.

38. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685-691.

39. Pfeffer MA, Braunwald E, Moye LA, et al. on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327: 669-677.

40. GISSI-3: effects of lisinopril and transdermal glyceril trinitrato singly and together on 6-week mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per lo Studio della Sopravvivenza nell´infarto Miocardico. Lancet 1994; 343: 1115-1122.

41. ISIS-4: a randomized factorial trial assesing early oral captopril, oral monitrate, and intravenous magnesium sulpahte in 58.050 patients with suspected acute myocardial infarction ISIS-4 collaborative group. Lancet 1995; 345: 669-685.

42. Cohn JN. The Management of Chronic Heart Failure. N Engl J Med 1996; 335: 490-498.

43. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with cronic heart failure treated with angiotensin-convertting-enzyme inhibitors. N Engl J Med 1993; 329: 1-7.

44. The Digitalis Investigation Group. The effet of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.

45. Eichhorn EJ, Bristow MR. Practical Guidelines for Initiation of Beta-Adrenergic Blockade in Patients with Chronic Heart Failure. Am J Cardiol 1997; 79: 794-798.

46. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardíaca en Argentina (GESICA). Lancet 1994; 344: 493-498.

47. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77-82.

48. Montner PK, Greene R, Murata GH, et al. Hemodynamic effects of nasal and face mask continous positive airway pressure. Am J Respir Crit Care Med 1994; 149: 1614-1618.

49. Cleland JGF, Dutka DP. Optimising heart failure pharmacotherapy: the ideal combination. Br Heart J 1994; 72(s): S73-S79.

50. Rafferty EB. Haemodynamic effects of diuretics in heart failure. Br Heart J 1994; 72(s): S44-S47.

51. Brater DC. Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J 1994; 72 (s): S40-S43.

52. McGregor M. The nitrates and myocardial ischemia. Circulation 1982; 66: 689-692.

53. Ginosar Y, Sprung CL. Raising the standard of hemodynamic monitoring: Targeting the practice or the practitioner?. Crit Care Med 1997; 25: 209-211.

54. Crexells C, Chatterjee K, Forrester JS et al. Optimal level of filling pressure in the left side of the heart in acute myocardial infarction. N Engl J Med 1977; 289: 1263-1266.

55. Packer M, O´Connor and the PRAISE Group. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335; 1107-1114.

56. Geraci SA. Pharmacologic approach in patients with heart failure. In: Chernow B (ed.). The Pharmacologic Approach to the Critically ill Patient. Williams and Wilkins, 1994; 80-94.